Genome-Wide Analysis of Molecular Changes in IL-12-Induced Control of Mammary Carcinoma via IFN-γ-Independent Mechanisms

Journal of Immunology

Volumn 172, Issue 7, 2004, Pages 4111-4122

  Shi, Xiaoyan ^a   Cao, Shanjin ^a   Mitsuhashi, Maki ^a   Xiang, Zhaoying ^a   Ma, Xiaojing ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; RECOMBINANT INTERLEUKIN 12;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOMA; CANCER CONTROL; CANCER INHIBITION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DISEASE MODEL; DRUG EFFICACY; FEMALE; GENE EXPRESSION PROFILING; GENOME ANALYSIS; METASTASIS; METASTASIS INHIBITION; MOUSE; NATURAL KILLER CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR VASCULARIZATION; UNINDEXED SEQUENCE; VASOCONSTRICTION;

EID: 1642279609     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.172.7.4111     Document Type: Article

References (52)

1. Ehrlich, P. 1909. Ueber den jetzigen stand der Karzinomforschung. Ned. Tijdschr. Geneschr. 5:273.
2. Burnet, F. 1957. Cancer-a biological approach. Brit. Med. J. 1:841.
3. Stutman, O. 1974. Tumor development after 3-methylcholanthrene in immunologically deficient athymic-nude mice. Science 183:534.
4. Dunn, G. P., A. T. Bruce, H. Ikeda, L. J. Old, and R. D. Schreiber. 2002. Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol. 3:991.
5. Browning, M. J., and W. F. Bodmer. 1992. MHC antigens and cancer: implications for T-cell surveillance. Curr. Opin. Immunol. 4:613.
6. Chen, L., S. Ashe, W. A. Brady, I. Hellstrom, K. E. Hellstrom, J. A. Ledbetter, P. McGowan, and P. S. Linsley. 1992. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 71:1093.
7. + T cells by B7-transfected melanoma cells. Science 259:368.
8. Coughlin, C. M., K. E. Salhany, M. S. Gee, D. C. LaTemple, S. Kotenko, X. Ma, G. Gri, M. Wysocka, J. E. Kim, L. Liu, et al. 1998. Tumor cell responses to IFN-γ affect tumorigenicity and response to IL-12 therapy and antiangiogenesis. Immunity 9:25.
9. Trinchieri, G. 1998. Interleukin-12: a cytokine at the interface of inflammation and immunity. Adv. Immunol. 70:83.
10. Trinchieri, G., and P. Scott. 1999. Interleukin-12: basic principles and clinical applications. Curr. Top. Microbiol. Immunol. 238:57.
11. Rook, A. H., G. S. Wood, E. K. Yoo, R. Elenitsas, D. M. Kao, M. L. Sherman, W. K. Witmer, K. A. Rockwell, R. B. Shane, S. R. Lessin, and E. C. Vonderheid. 1999. Interleukin-12 therapy of cutaneous T-cell lymphoma induces lesion regression and cytotoxic T-cell responses. Blood 94:902.
12. Rook, A. H., M. H. Zaki, M. Wysocka, G. S. Wood, M. Duvic, L. C. Showe, F. Foss, M. Shapiro, T. M. Kuzel, E. A. Olsen, et al. 2001. The role for interleukin-12 therapy of cutaneous T cell lymphoma. Ann. NY Acad. Sci. 941:177.
13. Ansell, S. M., T. E. Witzig, P. J. Kurtin, J. A. Sloan, D. F. Jelinek, K. G. Howell, S. N. Markovic, T. M. Habermann, G. G. Klee, P. J. Atherton, and C. Erlichman. 2002. Phase 1 study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma. Blood 99:67.
14. + T cells in melanoma patients receiving interleukin 12. Cancer Res. 60:3559.
15. Gollob, J. A., J. W. Mier, K. Veenstra, D. F. McDermott, D. Clancy, M. Clancy, and M. B. Atkins. 2000. Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-γ induction is associated with clinical response. Clin Cancer Res. 6:1678.
16. Lee, P., F. Wang, J. Kuniyoshi, V. Rubio, T. Stuges, S. Groshen, C. Gee, R. Lau, G. Jeffery, K. Margolin, et al. 2001. Effects of interleukin-12 on the immune response to a multipeptide vaccine for resected metastatic melanoma. J. Clin. Oncol. 19:3836.
17. Kang, W. K., C. Park, H. L. Yoon, W. S. Kim, S. S. Yoon, M. H. Lee, K. Park, K. Kim, H. S. Jeong, J. A. Kim, et al. 2001. Interleukin 12 gene therapy of cancer by peritumoral injection of transduced autologous fibroblasts: outcome of a phase I study. Hum. Gene Ther. 12:671.
18. + melanoma patients with MAGE-3 or MelanA peptide-pulsed autologous peripheral blood mononuclear cells plus recombinant human interleukin 12. Clin. Cancer Res. 7:895s.
19. Portielje, J. E., W. H. Kruit, M. Schuler, J. Beck, C. H. Lamers, G. Stoter, C. Huber, M. de Boer-Dennert, A. Rakhit, R. L. Bolhuis, and W. E. Aulitzky. 1999. Phase I study of subcutaneously administered recombinant human interleukin 12 in patients with advanced renal cell cancer. Clin. Cancer Res. 5:3983.
20. Miller, F. R., B. E. Miller, and G. H. Heppner. 1983. Characterization of metastatic heterogeneity among subpopulations of a single mouse mammary tumor: heterogeneity in phenotypic stability. Invasion Metastasis 33:22.
21. Pulaski, B. A., and S. Ostrand-Rosenberg. 1998. Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7.1 cell-based tumor vaccines. Cancer Res. 58:1486.
22. Aslakson, C. J., and F. R. Miller. 1992. Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res. 52:1399.
23. Morecki, S., L. Yacovlev, and S. Slavin. 1998. Effect of indomethacin on tumorigenicity and immunity induction in a murine model of mammary carcinoma. Int. J. Cancer 75:894.
24. Ostrand-Rosenberg, S., M. J. Grusby, and V. K. Clements. 2000. Cutting edge: STAT6-deficient mice have enhanced tumor immunity to primary and metastatic mammary carcinoma. J. Immunol. 165:6015.
25. Rakhmilevich, A. L., K. Janssen, Z. Hao, P. M. Sondel, and N. S. Yang. 2000. Interleukin-12 gene therapy of a weakly immunogenic mouse mammary carcinoma results in reduction of spontaneous lung metastases via a T-cell-independent mechanism. Cancer Gene Ther. 7:826.
26. Wang, Z. E., S. Zheng, D. B. Corry, D. K. Dalton, R. A. Seder, S. L. Reiner, and R. M. Locksley. 1994. Interferon-γ-independent effects of interleukin-12 administered during acute or established infection due to Leishmania major. Proc. Natl. Acad. Sci. USA 91:12932.
27. + T cells and granulocyte/macrophage colony-stimulating factor. J. Exp. Med. 188:133.
28. Hafner, M., W. Falk, B. Echtenacher, and D. N. Mannel. 1999. Interleukin-12 activates NK cells for IFN-γ-dependent and NKT cells for IFN-γ-independent antimetastatic activity. Eur. Cytokine Netw. 10:541.
29. Gri, G., C. Chiodoni, E. Gallo, A. Stoppacciaro, F. Y. Liew, and M. P. Colombo. 2002. Antitumor effect of interleukin (IL)-12 in the absence of endogenous IFN-γ, a role for intrinsic tumor immunogenicity and IL-15. Cancer Res. 62:4390.
30. Comes, A., E. Di Carlo, P. Musiani, O. Rosso, R. Meazza, C. Chiodoni, M. P. Colombo, and S. Ferrini. 2002. IFN-γ-independent synergistic effects of IL-12 and IL-15 induce anti-tumor immune responses in syngeneic mice. Eur. J. Immunol. 32:1914.
31. Pulaski, B. A., M. J. Smyth, and S. Ostrand-Rosenberg. 2002. Interferon-γ-dependent phagocytic cells are a critical component of innate immunity against metastatic mammary carcinoma. Cancer Res. 62:4406.
32. Eisen, M. B., P. T. Spellman, P. O. Brown, and D. Botstein. 1998. Cluster analysis and display of genome-wide expression patterns. Proc. Natl. Acad. Sci. USA 95:14863.
33. + tumor cells with interleukin-12 reduces established metastatic disease and stimulates immune effectors and monokine induced by interferon-γ. Cancer Immunol. Immunother. 49:34.
34. Tannenbaum, C. S., and T. A. Hamilton. 2000. Immune-inflammatory mechanisms in IFN-γ-mediated anti-tumor activity. Semin. Cancer Biol. 10:113.
35. Burke, F., R. G. Knowles, N. East, and F. R. Balkwill. 1995. The role of indoleamine 2,3-dioxygenase in the anti-tumour activity of human interferon-γ in vivo. Int. J. Cancer 60:115.
36. Thiemmara, V., L. Pays, E. Danty, F. Jourdan, E. Moyse, and P. Mehlen. 2002. Serine protease inhibitor Spi2 mediated apoptosis of olfactory neurons. Cell Death Differ. 9:1343.
37. Danesch, U., W. Hoeck, and G. M. Ringold. 1992. Cloning and transcriptional regulation of a novel adipocyte-specific gene, FSP27: CAAT-enhancer-binding protein (C/EBP) and C/EBP-like proteins interact with sequences required for differentiation-dependent expression. J. Biol. Chem. 267:7185.
38. Liang, L., M. Zhao, Z. Xu, K. K. Yokoyama, and T. Li. 2003. Molecular cloning and characterization of CIDE-3, a novel member of the cell-death-inducing DNA-fragmentation-factor (DFF45)-like effector family. Biochem. J. 370:195.
39. Rosen, B. S., K. S. Cook, J. Yaglom, D. L. Groves, J. E. Volanakis, D. Damm, T. White, and B. M. Spiegelman. 1989. Adipsin and complement factor D activity: an immune-related defect in obesity. Science 244:1483.
40. Asensio, V. C., J. Maier, R. Milner, K. Boztug, C. Kincaid, M. Moulard, C. Phillipson, K. Lindsley, T. Krucker, H. S. Fox, and I. L. Campbell. 2001. Interferon-independent, human immunodeficiency virus type 1 gp120-mediated induction of CXCL10/IP-10 gene expression by astrocytes in vivo and in vitro. J. Virol. 75:7067.
41. Colombo, M. P., and G. Trinchieri. 2002. Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev. 13:155.
42. Kutubuddin, M., H. J. Federoff, P. M. Challita-Eid, M. Halterman, B. Day, M. Atkinson, V. Planelles, and J. D. Rosenblatt. 1999. Eradication of pre-established lymphoma using herpes simplex virus amplicon vectors. Blood 93:643.
43. Bowen, M. A., J. Bajorath, M. D'Egidio, G. S. Whitney, D. Palmer, J. Kobarg, G. C. Starling, A. W. Siadak, and A. Aruffo. 1997. Characterization of mouse ALCAM (CD166): the CD6-binding domain is conserved in different homologs and mediates cross-species binding. Eur. J. Immunol. 27:1469.
44. Pawelec, G., and H. J. Buhring. 1991. Monoclonal antibodies to CD6 preferentially stimulate T-cell clones with γ/δ rather than α/β antigen receptors. Hum. Immunol. 31:165.
45. Osorio, L. M., M. Rottenberg, M. Jondal, and S. C. Chow. 1998. Simultaneous cross-linking of CD6 and CD28 induces cell proliferation in resting T cells. Immunology 93:358.
46. Jackson, D., O. V. Volpert, N. Bouck, and D. I. Linzer. 1994. Stimulation and inhibition of angiogenesis by placental proliferin and proliferin-related protein. Science 266:1581.
47. Ma, G. T., M. E. Roth, J. C. Groskopf, F. Y. Tsai, S. H. Orkin, F. Grosveld, J. D. Engel, and D. I. Linzer. 1997. GATA-2 and GATA-3 regulate trophoblast-specific gene expression in vivo. Development 124:907.
48. Lee, S., F. Talamantes, E. Wilder, D. Linzer, and D. Nathans. 1988. Trophoblastic giant cells of the mouse placenta as the site of proliferin synthesis. Endocrinology 122:1761.
49. Jackson, D., and D. I. H. Linzer. 1997. Proliferin transport and binding in the mouse fetus. Endocrinology 138:149.
50. Toft, D. J., S. B. Rosenberg, G. Bergers, O. Volpert, and D. I. H. Linzer. 2001. Reactivation of proliferin gene expression is associated with increased angiogenesis in a cell culture model of fibrosarcoma tumor progression. Proc. Natl. Acad. Sci. USA 98:13055.
51. Bodey, B., B. Bodey, Jr., A. M. Groger, S. E. Siegel, and H. E. Kaiser. 2001. Invasion and metastasis: the expression and significance of matrix metalloproteinases in carcinomas of the lung. In Vivo 15:175.
52. Spinetti, G., G. Camarda, G. Bernardini, S. Romano Di Peppe, M. C. Capogrossi, and M. Napolitano. 2001. The chemokine CXCL13 (BCA-1) inhibits FGF-2 effects on endothelial cells. Biochem. Biophys. Res. Commun. 289:19.